Personalized prostate cancer therapy that preserves quality of life.

An Unmet Need

Tens of thousands of men each year with prostate cancer seek treatments that impact their quality of life with significant risks (>50%) of sexual or urinary dysfunction.

At Avenda Health, we believe patients should not have to choose between treating their prostate cancer and keeping their quality of life.

Our Technology

Our platform uses a laser to precisely treat prostate cancer* in an outpatient setting without compromising urinary or sexual function. Personalized treatment plans are created using AI-based cancer margin prediction and confirmed using our proprietary real-time feedback sensor.

*This is an investigational device not currently available for clinical use.

How It Works

The Avenda Health platform delivers targeted treatment through focal laser ablation, minimizing the impact to healthy tissue.

Plan

Intelligent Margin Prediction

Treat

Real-time Feedback and Control

Confirm

Precise Ablation

Our Team

Our world-class team of innovators comprising of experts in Urology, Artificial Intelligence (AI), and Medical Devices.

Shyam Natarajan, PhD

Founder / CEO
  • Expertise in image-guided interventions, machine learning, and embedded systems
  • Instrumental in the commercialization of targeted prostate biopsy creating and executing the foundational validation studies
  • Led an NIH-funded lab as a professor at UCLA Urology, Surgery, and Bioengineering

Leonard S. Marks, MD

Founder / CMO
  • Professor and deKernion Endowed Chair of Urology at UCLA
  • Pioneer and world leader in Targeted Prostate Biopsy, Active Surveillance, and Focal Therapy
  • 150+ peer-reviewed publications, 30+ clinical trials, 10+ federal grants

Brittany Berry-Pusey, PhD

Founder / COO
  • 8+ years in Market Access, Regulatory Strategy, and Business Development for medical device and digital health
  • UCLA Anderson School of Management and Stanford Graduate School of Business training
  • Expertise in Cardiology, Diabetes, Oncology, and Urology

Joshua Shubert

AI Lead
  • M.S. in Electrical Engineering from Johns Hopkins
  • Industry experience in cloud-based medical software
  • Background in deep learning, medical imaging, and robotics

Jeremy Bong

Sr. Cloud Engineer
  • B.S. in Computer Science at University of Waterloo
  • Background in cloud architecture and full-stack
  • 9+ years experience in professional software development

Prateek Bhatnagar

Software Engineer
  • M.S. in Computer Science from Johns Hopkins
  • Background in medical imaging, mixed reality, and networking

Mike Klein

Board of Directors
  • Chairman and CEO, iCAD Medical (NSDQ: ICAD)
  • Serial entrepreneur with numerous successful exits in oncology, AI, and medical device
  • Seasoned leader and executive in urology, oncology, and AI

Simon Stertzer, MD, FACC, FAHA, FACP

Scientific Advisory Board
  • Pioneer in clinical cardiology, with contributions including the advancement of rotational atherectomy and drug delivery stents
  • Serial innovator with numerous successful exists in medical device and therapeutics
  • Professor Emeritus at Stanford

Recognition

1st Place in Los Angeles MedTech Innovator Competition, and selected for MedTech Innovator accelerator program (20 of 600 companies). MedTech Innovator Class of 2017.

“Improving margin prediction with machine learning” honored as Best Paper at the 2019 Engineering and Urology Society meeting.

Finalist, American Diabetes Association HealthTech Showcase (Nov 2019)

Grand Prize Winner at the 2019 SPIE Startup Challenge. (Feb 2019)

Finalist, MedCity INVEST (Apr 2019)

Selected for the nVidia Inception Deep Learning Incubator program (Class of 2018)

Publications

Contact Us